Abstract
Metabolism of androgens includes glucuronidation, the major pathway of steroid elimination in several steroid target tissues. Glucuronidation is catalysed by UDP-glucuronosyltransferases (UGTs). UGT2B17 has been shown to be particularly active against androgens and is highly abundant in the prostate. Recently, we discovered that deletion of the UGT2B17 gene is associated with low or undetectable urinary testosterone levels. Here, we determined the phenotypic outcome of the deletion by quantifying the UGT2B17 mRNA expression in normal prostate tissues in individuals with different genotypes. Additionally, the frequency of UGT2B17 deletion polymorphism was studied in a Swedish population-based case–control study including 176 patients diagnosed with prostate cancer and 161 controls. We found that the individuals homozygous for the insertion allele expressed 30 times more UGT2B17 mRNA in prostate tissue than the heterozygotes. Carriers of the deletion allele had a significantly increased risk of prostate cancer (OR=2.07; 95% CI=1.32–3.25). In conclusion, these results show the UGT2B17 deletion polymorphism is associated with prostate cancer risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- Del:
-
deletion
- DHT:
-
dihydrotestosterone
- Ins:
-
insertion
- PCR:
-
polymerase chain reaction
- UGT:
-
uridine diphosphoglucuronosyl tranferases
References
Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652–661.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ . Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.
Lipsett MB . Estrogen use and cancer risk. J Am Med Assoc 1977; 237: 1112–1115.
Denis L, Mahler C . Prostatic cancer. An overview. Acta Oncol 1990; 29: 665–677.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.
Imamov O, Lopatkin NA, Gustafsson JA . Estrogen receptor beta in prostate cancer. N Engl J Med 2004; 351: 2773–2774.
Hsing AW . Hormones and prostate cancer: what's next? Epidemiol Rev 2001; 23: 42–58.
Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887–889.
Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ . Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991; 72: 1242–1248.
Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 1999; 69: 413–423.
Barbier O, Lapointe H, El Alfy M, Hum DW, Belanger A . Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab 2000; 85: 4819–4826.
Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A . Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142: 778–787.
Wilson III W, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84: 707–714.
Murata M, Warren EH, Riddell SR . A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197: 1279–1289.
Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91: 687–693.
Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15: 1473–1478.
Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW . Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7: 317–325.
MacLeod SL, Nowell S, Plaxco J, Lang NP . An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case–control study of prostate cancer. Ann Surg Oncol 2000; 7: 777–782.
Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S et al. Asp85tyr polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004; 171: 2484–2488.
Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, Belanger A . Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 1997; 138: 2998–3005.
Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F et al. 5Alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002; 12: 307–312.
Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E . Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635–639.
Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999; 9: 333–340.
Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408.
Acknowledgements
This work was supported by grants from the Swedish Cancer Society, World Anti-Doping Agency (WADA) and the Swedish Foundation for Strategic Research.
Author information
Authors and Affiliations
Corresponding author
Additional information
Duality of Interest
None declared.
Rights and permissions
About this article
Cite this article
Karypidis, AH., Olsson, M., Andersson, SO. et al. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J 8, 147–151 (2008). https://doi.org/10.1038/sj.tpj.6500449
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500449
Keywords
This article is cited by
-
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer
British Journal of Cancer (2023)
-
Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression
Hormones and Cancer (2016)
-
UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family
BMC Genetics (2013)
-
Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study
BMC Cancer (2013)
-
Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men
Molecular Biology Reports (2013)